Skip to main content

Denmark's MPI To Develop Cancer Drug Response Tests on Affy Platform

NEW YORK (GenomeWeb News) – Affymetrix said today that Medical Prognosis Institute, a cancer diagnostic firm based in Denmark, will use the Affy microarray platform to develop drug sensitivity prediction and prognostic tools for patients with cancer.
Under the terms of the “Powered by Affymetrix” agreement, MPI gains non-exclusive access to Affy’s technology to develop and commercialize tools that will identify patients likely to respond to anti-cancer drugs.
The partnership “also boosts the probability of successful anti-cancer drug development in partnership with drug companies," Jesper Drejet, president and CEO of MPI, said in a statement.
Drejet added that the company is “confident” that it will be able to obtain regulatory clearance and begin commercializing its tests within one to two years.
Affymetrix and its PbA partners are currently developing more than 20 different tests on the Affy microarray platform, the company said.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.